Previous in vitro studies have shown that MAP3K19 activated the ERK and JNK signaling pathways in vitro kinase assays and that MAP3K19 expression plasmid transiently transfected and activated the ERK and JNK pathways in cancer cell lines [30]. The gene discussed is MAP3K19; the disease is cancer.